Humana maintains a conservative capital structure with a debt-to-equity ratio of 0.66 and a current ratio of 1.77, indicating adequate short-term liquidity coverage. The company holds $4.95 billion…
ResMed maintains a highly conservative capital structure with a debt-to-equity ratio of 0.04 and a current ratio of 3.01, indicating strong short-term liquidity coverage. The balance sheet holds $1…
Stryker maintains a leveraged capital structure with $14.19 billion in long-term debt against $3.39 billion in cash and equivalents, resulting in a negative net cash position. The debt-to-equity ra…
UnitedHealth Group maintains a capital structure characterized by significant leverage, with long-term debt of $71.44 billion against total equity of $103.90 billion, resulting in a debt-to-equity…
Quantum-Si maintains a debt-free capital structure with a debt-to-equity ratio of 0.0 and a robust current ratio of 12.6, supported by $36.2 million in cash and equivalents and $154.2 million in to…
Elevance Health, Inc. (ELV) is currently classified as Commercial Banks within Banks (Financials). Classification confidence: 0.81 (rule-based classification). Capital structure on the latest snaps…
Envoy Medical, Inc. (COCH) is currently classified as Commercial Banks within Banks (Financials). Classification confidence: 0.81 (rule-based classification). Capital structure on the latest snapsh…
Cencora, Inc. (COR) is currently classified as Commercial Banks within Banks (Financials). Classification confidence: 0.81 (rule-based classification). Capital structure on the latest snapshot: tot…
Aardvark Therapeutics maintains a pristine balance sheet with zero debt and a current ratio of 8.06, indicating exceptional short-term liquidity. The company holds $62.4 million in cash and equival…
AbbVie’s capital structure is characterized by significant leverage and negative shareholders' equity, resulting in a debt-to-equity ratio of -9.7 and a return on equity of -0.6349. The balance she…
AbCellera maintains a debt-free capital structure with a debt-to-equity ratio of 0.0 and a robust current ratio of 14.05, indicating strong short-term liquidity coverage. The balance sheet holds $7…
Arbutus Biopharma maintains a highly liquid balance sheet with $23.7 million in cash and equivalents and $71.5 million in current marketable securities, totaling $95.2 million in liquid assets. Tot…
ACME UNITED CORP maintains a conservative capital structure with a debt-to-equity ratio of 0.28 and a strong current ratio of 4.57, indicating ample short-term liquidity coverage. The company holds…
Aethlon Medical maintains a debt-free capital structure with a debt-to-equity ratio of 0.0 and a current ratio of 3.85, indicating strong short-term liquidity coverage. The company holds $5.03 mill…
Agenus maintains a negative equity position of $221.2 million against total assets of $186.5 million, resulting in a debt-to-equity ratio of -0.14. The balance sheet shows $35.0 million in cash and…
Alnylam maintains a robust liquidity position with $1.71 billion in cash and equivalents and a current ratio of 3.05. The balance sheet shows total assets of $5.56 billion against total liabilities…
Altimmune maintains a highly liquid balance sheet with $97.6 million in cash and equivalents against $51.6 million in total liabilities, resulting in a current ratio of 29.56 and a debt-to-equity r…
ANI Pharmaceuticals maintains a conservative capital structure with a debt-to-equity ratio of 0.54 and a current ratio of 3.12, indicating strong short-term liquidity coverage. The balance sheet ho…
Annexon maintains a strong liquidity position with $175.2 million in cash and equivalents against total liabilities of $58.4 million, resulting in a current ratio of 6.35 and zero debt-to-equity. T…
Alto Neuroscience maintains a highly liquid balance sheet, holding $263.8 million in cash and equivalents against total liabilities of $32.9 million. The current ratio stands at 20.52, indicating s…
Apyx Medical maintains a capital structure characterized by high leverage and significant liquidity constraints. Total long-term debt stands at $35.1 million against total equity of $12.8 million,…
Arcturus Therapeutics maintains a strong liquidity position with $211.4 million in cash and equivalents against total liabilities of $54.0 million, resulting in a current ratio of 6.31 and zero deb…
Armata Pharmaceuticals exhibits a distressed capital structure with negative total equity of $-311.6 million against total assets of $69.8 million. The balance sheet shows total liabilities of $381…
Arcutis maintains a capital structure characterized by significant leverage relative to equity, with a debt-to-equity ratio of 0.58 and total liabilities of $270.4 million against $189.6 million in…
AtaiBeckley maintains a capital structure characterized by high leverage relative to equity, with short-term debt of $166.8 million against total equity of $198.7 million, resulting in a debt-to-eq…
ATOSSA THERAPEUTICS maintains a debt-free capital structure with $31.7 million in cash and equivalents against $7.5 million in total liabilities, resulting in a current ratio of 4.92 and a debt-to-…
AtriCure maintains a conservative capital structure with $146.2 million in cash and equivalents against $61.0 million in long-term debt, resulting in a low debt-to-equity ratio of 0.12. The balance…
HeartBeam maintains a fragile capital structure characterized by high liquidity risk and negative equity returns. The company holds $2.04 million in cash and equivalents against $3.29 million in to…
Bausch & Lomb maintains a capital structure characterized by significant leverage, with long-term debt of $5.05 billion and short-term debt of $28 million against total equity of $6.38 billion. The…
CRYO CELL INTERNATIONAL INC (CCEL) is currently classified as Commercial Banks within Banks (Financials). Classification confidence: 0.81 (rule-based classification). Capital structure on the lates…
Cadiz Inc. maintains a highly leveraged capital structure with total liabilities of $130.5 million against total equity of $15.6 million, resulting in a debt-to-equity ratio of 5.48. The balance sh…
Creative Medical Technology Holdings maintains a debt-free capital structure with a debt-to-equity ratio of 0.0 and a current ratio of 19.69, indicating strong short-term liquidity coverage relativ…
Cognition Therapeutics maintains a debt-free capital structure with a debt-to-equity ratio of 0.0 and a current ratio of 5.92, indicating strong short-term liquidity coverage. The balance sheet hol…
Celldex maintains a debt-free capital structure with a debt-to-equity ratio of 0.0 and a robust current ratio of 8.92, indicating strong short-term liquidity coverage. The balance sheet holds $357.…
Centene maintains a capital structure supported by $21.26 billion in cash and equivalents against $16.31 billion in long-term debt and $63 million in short-term debt, resulting in a debt-to-equity…
Cocrystal Pharma maintains a debt-free capital structure with a debt-to-equity ratio of 0.0, supported by $7.025 million in cash and equivalents against total liabilities of $3.31 million. The curr…
Co-Diagnostics maintains a debt-free capital structure with a debt-to-equity ratio of 0.0. The balance sheet holds $8.23 million in cash and equivalents against $5.46 million in total liabilities,…
Catalyst Pharmaceuticals maintains a fortress balance sheet with $755.9 million in cash and equivalents against total liabilities of $134.9 million, resulting in a debt-to-equity ratio of 0.0 and a…
Cardiff Oncology operates with a capital structure characterized by zero debt and a current ratio of 3.27, indicating strong short-term liquidity coverage relative to liabilities. The company holds…
Corvus Pharmaceuticals maintains a debt-free capital structure with a debt-to-equity ratio of 0.0 and a robust current ratio of 19.81, indicating strong short-term liquidity coverage. The balance s…
CytomX maintains a debt-free capital structure with a debt-to-equity ratio of 0.0 and a robust current ratio of 10.38, indicating strong short-term liquidity coverage. Total equity stands at $319.9…
Delcath Systems maintains a highly liquid balance sheet with $41.3 million in cash and equivalents against total liabilities of $12.1 million, resulting in a current ratio of 11.24 and zero debt-to…
Damora Therapeutics maintains a robust liquidity position with $532.9 million in cash and equivalents against total liabilities of $23.8 million, resulting in a current ratio of 22.48 and a debt-to…
DexCom maintains a robust liquidity position with $1.105 billion in cash and equivalents and a current ratio of 1.73. The balance sheet shows total assets of $6.455 billion against total liabilitie…
Edgewise Therapeutics maintains a debt-free capital structure with a debt-to-equity ratio of 0.0 and a robust current ratio of 22.61, indicating strong short-term liquidity coverage. The balance sh…
Exelixis maintains a robust capital structure characterized by zero debt and a current ratio of 3.26, indicating strong short-term liquidity coverage. The balance sheet holds $226.2 million in cash…
GeoVax Labs maintains a fragile capital structure characterized by high liquidity risk and substantial dilution pressure. The company holds $1.27 million in cash and equivalents against total liabi…
Hyperion DeFi maintains a debt-free capital structure with a debt-to-equity ratio of 0.0 and a current ratio of 1.97, indicating adequate short-term liquidity coverage. The balance sheet holds $70.…
Incyte maintains a robust capital structure characterized by zero debt-to-equity and a current ratio of 3.68, indicating strong short-term liquidity. The balance sheet holds $3.46 billion in cash a…
We'll email you once when Handelsavisen goes live. No spam, no other use.
By signing up you agree to receive a single launch-day notification from Handelsavisen.